Imaging Mass Cytometry Maps Immune Remodeling After PSMA α- and β-Radioligand Therapy in Prostate Cancer (EANM 2026) - Sep 29, 2026 - Abstract #EP-0052; "Aim/Introduction: Despite the clinical success of Pluvicto in mCRPC, durable responses remain elusive, reflecting an incomplete understanding of treatment-induced tumor microenvironment (TME) changes... High-dimensional IMC profiling shows αRLT induces a distinct prostate TME remodeling vs. βRLT, with increased cytotoxic T cells and M1 macrophages, reduced immunosuppression, and deeper tumor infiltration. The 48h-6 day post-αRLT window emerges as a promising window for combining with immune checkpoint inhibitors."
IO biomarker • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • CASP3 • CCR2 • CD31 • CD8 • CDH1 • FOXP3 • GZMB • ITGAM • MRC1 • PECAM1 • PTPRC • STING • VIM
|
|
C. Mona; J. J. Liang; I. Fajnorova; B. Louis; B. Comin-Anduix
|